Please assess the completion status of the following clinical trial:

Trial Title: Ambrisentan in Single Ventricle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 24 months; ≤120 months.~2. History of congenital heart disease with severe hypoplasia of a right or left ventricle.~3. Undergoing Fontan surgery as part of standard clinical care.~4. Availability and willingness of the parent/legally authorized representative to provide written informed consent and, as appropriate, assent from the child.~Exclusion Criteria:~1. History of serious adverse event related to ambrisentan administration.~2. History of ambrisentan exposure within 48 hours of the study.~3. Presence of pulmonary venous obstruction.~4. Treatment with cyclosporin.~5. Any of the following - as determined by the attending physician~   * Significant hemodynamic instability~  * Sepsis.~  * Need for ECMO support.~6. Renal failure defined as serum creatinine \> 2 times higher than the upper limit of normal.~7. Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase \> 3 times higher than the upper limit of normal.~8. Thrombocytopenia defined as a platelet count \< 50 000 cells/µL.~9. Leukopenia defined as white blood cells \< 2500 cells/µL.~10. Anemia defined as hemoglobin \< 8mg/dL.~11. Atrial hypertension (mean LA pressure \> 12mm Hg).

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 120 Months
- Healthy Volunteers: f

Study Arms:
- Ambrisentan (Type: ACTIVE_COMPARATOR): Oral ambrisentan 2.5 - 5 mg, single dose, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo 2.5 - 5 mg, single dose, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).